Unravelling the Mechanism of Action of Combined Targets in Melanoma

SysQuant® Global Phosphoproteomics

Goal – Analyse the context in which melanoma-derived cell lines exploit MEK and PI3K signalling to overcome BRAF V600E resistance.

Outcome – Identification of a number of common effects of combination therapy irrespective of the second target as well as specific effects dependant on targeting either MEK or PI3K.

Collaborators – Moffitt Cancer Centre, Tampa, Florida

View all case studies